HC Wainwright & Co. Reiterates Neutral on Prelude Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Neutral rating on Prelude Therapeutics (NASDAQ:PRLD) and maintained a $5 price target.
August 15, 2024 | 10:36 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Neutral rating on Prelude Therapeutics and maintained a $5 price target.
The reiteration of a Neutral rating and maintenance of the $5 price target suggests that the analyst does not foresee significant short-term changes in the stock's performance. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100